English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

disability, leading to a reduced quality of life. Moreover, bone metastases in patients with CRPC are independently associated with increased mortality. In consideration of the needs of older patient population, the optimal approach of elderly PC patients poses a particular clinical challenge. Over last years, several novel drugs for CRPC have been introduced, such as the new taxan agent cabazitaxel, immunotherapy (sipuleucel-T), RANK-L inhibitor denosumab, androgen biosynthesis inhibitors (abiraterone acetate), and androgen receptor antagonists (enzalutamide). These antitumoral agents have changed therapeutic management of CRPC patients, although there is still the need to define an appropriate sequencing for their application to maximize patient benefit and minimize costs. In this evolving scenario, a first-in-class alpha-emitting radionuclide, 223Radichloride, has been recently approved for the treatment of CRPC patients with symptomatic bone metastases and no known visceral disease. FDA approval of 223Ra came in May 2013 as a result of the findings of the international, randomized, double-blind alpharadin in symptomatic prostate cancer (ALSYMPCA) Phase III trial that evaluated efficacy on overall survival of 223Ra treatment versus placebo in patients with mCRPC [2]. Thanks to its analogy to calcium, 223Ra targets areas of high osteoblastic activity such as sites of bone metastases, delivering high-energy short-range alpha particle radiation. Alpha particles are characterized by a high-linear energy transfer (LET) to surrounding tissues delivered in a short path (<100 μm), inducing double-stranded breaks in DNA with a local cytotoxic effect that is, notably, independent from dose rate, oxygen level, and cell cycle status [3]. The short penetration range of alpha particles (approximately corresponding to 2–10 cell diameters) determines a low dose of radiation delivered to normal bone-marrow cell population, with minimal hematological adverse effects. Results

aging clinical and experimental research

223Ra-dichloride therapy in an elderly bone metastatic castration-resistant prostate cancer patient: a case report presentation and comparison with existing literature